Urodilatin and pentoxifylline prevent the early onset of escherichia coli-induced acute renal failure in a model of isolated perfused rat kidney

Kidney and Blood Pressure Research

Volumn 32, Issue 2, 2009, Pages 81-90

  Groesdonk, Heinrich V ^a   Bauer, Alexander ^a   Kreft, Burkhard ^b   Heringlake, Matthias ^a   Paarmann, Hauke ^a   Pagel, Horst ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b Department of Dermatology   (Germany)

Author keywords

Acute renal failure; Isolated perfused rat kidney; Pentoxifylline; Sepsis; Urodilatin

Indexed keywords

PENTOXIFYLLINE; THEOPHYLLINE; TUMOR NECROSIS FACTOR ALPHA; URODILATIN;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE MODEL; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; ESCHERICHIA COLI; EX VIVO STUDY; GLOMERULUS FILTRATION RATE; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY PERFUSION; KIDNEY VASCULAR RESISTANCE; MALE; MICTURITION; NONHUMAN; PARAMETER; PRIORITY JOURNAL; RAT; RENAL PROTECTION; TREATMENT OUTCOME;

ANIMALS; ATRIAL NATRIURETIC FACTOR; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI INFECTIONS; HUMANS; KIDNEY; KIDNEY FAILURE, ACUTE; MALE; PENTOXIFYLLINE; PEPTIDE FRAGMENTS; PERFUSION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 62849114792     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000209378     Document Type: Article

References (55)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29: 1303-1310.
2. Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546-1554.
3. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP: The natural history of the systemic inflammatory response syndrome. A prospective study. JAMA 1995;273:117-123.
4. Ronco C, Ghezzi P, Bellomo R, Brendolan A: New perspectives in the treatment of acute renal failure. Blood Purif 1999;17:166-172.
5. Arad G, Levy R, Hillman D, Kaempfer R: Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation. Nat Med 2000; 6: 414-421.
6. Creteur J, Vincent JL: Hemoglobin solutions: an 'all-in-one' therapeutic strategy in sepsis? Crit Care Med 2000;28:894-896.
7. Galban C, Montejo JC, Mesejo A, Marco P, Celaya S, Sanchez-Segura JM, Farre M, Bryg DJ: An immune-enhancing enteral diet reduces mortality rate and episodes of bactere- mia in septic intensive care unit patients.Crit Care Med 2000; 28:643-648.
8. Schrier RW, Wang W: Acute renal failure and sepsis. N Engl J Med 2004;351:159-169.
9. Schrier RW, Wang W, Poole B, Mitra A: Acute renal failure: definitions, diagnosis, pathogenesis, and therapy. J Clin Invest 2004;114: 5-14.
10. Thijs A, Thijs LG: Pathogenesis of renal failure in sepsis. Kidney Int Suppl 1998;66:S34-S37.
11. Wang W, Falk SA, Jittikanont S, Gengaro PE, Edelstein CL, Schrier RW: Protective effect of renal denervation on normotensive endo- toxemia-induced acute renal failure in mice. Am J Physiol Renal Physiol 2002; 283:F583- F587.
12. Camussi G, Ronco C, Montrucchio G, Pic- coli G: Role of soluble mediators in sepsis and renal failure. Kidney Int Suppl 1998;66:S38-S42.
13. Cunningham PN, Dyanov HM, Park P, Wang J, Newell KA, Quigg RJ: Acute renal failure in endotoxemia is caused by TNF acting directly on TNF receptor-1 in kidney. J Immunol 2002;168:5817-5823.
14. Henninger DD, Panes J, Eppihimer M, Russell J, Gerritsen M, Anderson DC, Granger DN: Cytokine-induced VCAM-1 and ICAM- 1 expression in different organs of the mouse. J Immunol 1997;158:1825-1832.
15. Kacimi R, Karliner JS, Koudssi F, Long CS: Expression and regulation of adhesion molecules in cardiac cells by cytokines: response to acute hypoxia. Circ Res 1998; 82: 576-586.
16. Knotek M, Rogachev B, Wang W, Ecder T, Melnikov V, Gengaro PE, Esson M, Edelstein CL, Dinarello CA, Schrier RW: Endotoxemic renal failure in mice: role of tumor necrosis factor independent of inducible nitric oxide synthase. Kidney Int 2001;59:2243-2249.
17. Kreft B, Pagel H: Virulence factors of Escherichia coli contribute to acute renal failure.Exp Nephrol 2000; 8: 244-251.
18. Sullivan GW, Carper HT, Novick WJ Jr, Mandell GL: Inhibition of the inflammatory action of interleukin-1 and tumor necrosis factor-aα on neutrophil function by pentoxifylline. Infect Immun 1988;56:1722-1729.
19. Zabel P, Schade FU, Schlaak M: Inhibition of endogenous TNF formation by pentoxifyl- line. Immunobiology 1993;187:447-463.
20. Aviado DM, Porter JM: Pentoxifylline: a new drug for the treatment of intermittent clau- dication. Mechanism of action, pharmacoki- netics, clinical efficacy and adverse effects. Pharmacotherapy 1984;4:297-307.
21. Gillings DB: Pentoxifylline and intermittent claudication: review of clinical trials and cost-effectiveness analyses. J Cardiovasc Pharmacol 1995;25(suppl 2):S44-S50.
22. Heringlake M, Heinrichs G, Weber CF, Rosemann C, Bahlmann L, Eichler W, Mis- feld M, Heinze H: The anti-inflammatory and organ-protective effects of pentoxifyl- line during cardiac surgery. Appl Cardio- pulm Pathophysiol 2007;11:17-23.
23. Marukawa S, Hatake K, Wakabayashi I, Hishida S: Vasorelaxant effects of oxpenti- fylline and theophylline on rat isolated aorta. J Pharm Pharmacol 1994; 46:342-345.
24. Muller R, Lebrach F: Haemorheological role of platelet aggregation and hypercoagulabil- ity in microcirculation: therapeutical approach with pentoxifylline. Pharmathera-peutica 1980; 2:372-379.
25. Muller R, Schroer R: Cerebrovascular circulatory disorders: new aspects of pathophysiology and therapy. J Med 1979;10:347-364.
26. Poggesi L, Scarti L, Boddi M, Masotti G, Serneri GG: Pentoxifylline treatment in patients with occlusive peripheral arterial disease. Circulatory changes and effects on prostaglandin synthesis. Angiology 1985;36: 628-637.
27. Osswald H, Gleiter C, Muhlbauer B: Thera-peutic use of theophylline to antagonize renal effects of adenosine. Clin Nephrol 1995;43(suppl 1):S33-S37.
28. Endlich K, Forssmann WG, Steinhausen M: Effects of urodilatin in the rat kidney: Comparison with ANF and interaction with va- soactive substances. Kidney Int 1995;47: 1558-1568.
29. Forssmann WG: Urodilatin (ularitide, INN): a renal natriuretic peptide. Molecular biology and clinical importance. Nephron 1995; 69:211-222.
30. Heringlake M, Bahlmann L, Klaus S, Wagner K, Schmucker P, Pagel H: Effects of angiotensin II and the AT-1 receptor antagonist losartan on the renal excretion of urodilatin. Kidney Blood Press Res 2001;24:79-83.
31. Lin JJ, Churchill PC, Bidani AK: Theophyl- line in rats during maintenance phase of post-ischemic acute renal failure. Kidney Int 1988; 33: 24-28.
32. Schmidt FH: Enzymatic determination of glucose and fructose simultaneously (in German). Klin Wochenschr 1961;39:1244-1247.
33. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
34. Schmidt C, Hocherl K, Bucher M: Regulation of renal glucose transporters during severe inflammation. Am J Physiol Renal Physiol 2007; 292:F804-F811.
35. Gao H, Evans TW, Finney SJ: Bench-to-bedside review: sepsis, severe sepsis and septic shock - does the nature of the infecting organism matter? Crit Care 2008;12:213.
36. Wang W, Zolty E, Falk S, Basava V, Reznikov L, Schrier R: Pentoxifylline protects against endotoxin-induced acute renal failure in mice. Am J Physiol Renal Physiol 2006; 291: F1090-F1095.
37. Bahlmann L, Pagel H, Klaus S, Heringlake M, Schmucker P, Wagner K: Pentoxifylline improves circulatory and metabolic recovery after cardiopulmonary resuscitation. Resuscitation 2000;47:191-194.
38. Sampaio EP, Moraes MO, Nery JA, Santos AR, Matos HC, Sarno EN: Pentoxifylline decreases in vivo and in vitro tumour necrosis factor-aα production in lepromatous leprosy patients with erythema nodosum leprosum. Clin Exp Immunol 1998; 111: 300-308.
39. Wenisch C, Looareesuwan S, Wilairatana P, Parschalk B, Vannapann S, Wanaratana V, Wernsdorfer W, Graninger W: Effect of pentoxifylline on cytokine patterns in the therapy of complicated Plasmodium falciparum malaria. Am J Trop Med Hyg 1998;58: 343-347.
40. 1b and the phosphodiesterase inhibitor pentoxifylline in patients with re- lapsing-remitting multiple sclerosis. Ann Neurol 1998; 44:27-34.
41. 1b treatment in patients with multiple sclerosis. Neurology 1996; 47: 604.
42. Noel C, Hazzan M, Coppin MC, Codaccioni MX, Pruvot FR, Labalette M, Lelievre G: A randomized controlled trial of pentoxifyl- line for the prevention of delayed graft function in cadaveric kidney graft. Clin Transplant 1997;11:169-173.
43. Staubach KH, Schroder J, Stuber F, Gehrke K, Traumann E, Zabel P: Effect of pentoxi- fylline in severe sepsis: results of a randomized, double-blind, placebo-controlled study.Arch Surg 1998; 133: 94-100.
44. Hoffmann H, Markewitz A, Kreuzer E, Reichert K, Jochum M, Faist E: Pentoxifyl- line decreases the incidence of multiple organ failure in patients after major cardiotho- racic surgery. Shock 1998; 9: 235-240.
45. Boldt J, Brosch C, Lehmann A, Haisch G, Lang J, Isgro F: Prophylactic use of pentoxi- fylline on inflammation in elderly cardiac surgery patients. Ann Thorac Surg 2001; 71: 1524-1529.
46. Boldt J, Brosch C, Piper SN, Suttner S, Lehmann A, Werling C: Influence of prophylactic use of pentoxifylline on postoperative organ function in elderly cardiac surgery patients. Crit Care Med 2001; 29: 952-958.
47. Garcia RE: Therapeutic strategies in the prevention of acute renal failure. Ren Fail 1997; 19: 231-235.
48. Kiemer AK, Vollmar AM, Bilzer M, Gerwig T, Gerbes AL: Atrial natriuretic peptide reduces expression of TNF-aα MRNA during reperfusion of the rat liver upon decreased activation of NF-kB and AP-1. J Hepatol 2000;33: 236-246.
49. Schramm L, Heidbreder E, Lukes M, Weierich T, Lopau K, Zimmermann J, Wanner C: Endotoxin-induced acute renal failure in the rat: effects of urodilatin and diltiazem on renal function. Clin Nephrol 1996; 46: 117-124.
50. Wiebe K, Meyer M, Wahlers T, Zenker D, Schulze F, Michels P, Dalichau H, Mohr FW, Borst H, Forssmann WG: Acute renal failure following cardiac surgery is reverted by administration of urodilatin (INN: ularitide). Eur J Med Res 1996; 1: 259-265.
51. Meyer M, Richter R, Forssmann WG: Urodi- latin, a natriuretic peptide with clinical implications. Eur J Med Res 1998; 3: 103-110.
52. Schramm L, Heidbreder E, Kartenbender K, Schmitt A, Zimmermann J, Lopau K, Ling H, Heidland A: Effects of urodilatin and diltia- zem on renal function in ischemic acute renal failure in the rat. Am J Nephrol 1995; 15:418-426.
53. Schramm L, Heidbreder E, Schaar J, Lopau K, Zimmermann J, Gotz R, Ling H, Heidland A: Toxic acute renal failure in the rat: effects of diltiazem and urodilatin on renal function. Nephron 1994; 68:454-461.
54. Bell M, Jackson E, Mi Z, McCombs J, Car- cillo J: Low-dose theophylline increases urine output in diuretic-dependent critically ill children. Intensive Care Med 1998; 24: 1099-1105.
55. Frede S, Fandrey J, Pagel H, Hellwig T, Jelk- mann W: Erythropoietin gene expression is suppressed after lipopolysaccharide or inter- leukin-1ß injections in rats. Am J Physiol 1997;273:R1067-R1071.